Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01610 vs Topotecan in Recurrent SCLC
NCT06128837Phase 3Recruiting
- Sponsor
- Luye Pharma Group
- Start
- Mar 2024
- Primary completion
- Jun 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan liposome injection in small cell lung cancer (SCLC), sponsored by Luye Pharma Group. Primary endpoint: Overall Survival at 52 months. Started Mar 2024; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06128837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128837.